CD19 and B-cell neoplasm: Simultaneously, following genetic reconfiguration to foster the expression of CD19-specific chimeric antigen receptor (CAR), it can be effectively utilized for addressing progressive B-cell neoplasms, boasting robust antineoplastic outcomes.